| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GNPDA2 |
| Uniprot No | Q8TDQ7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-276aa |
| 氨基酸序列 | MRLVILDNYDLASEWAAKYICNRIIQFKPGQDRYFTLGLPTGSTPLGCYKKLIEYHKNGHLSFKYVKTFNMDEYVGLPRNHPESYHSYMWNNFFKHIDIDPNNAHILDGNAADLQAECDAFENKIKEAGGIDLFVGGIGPDGHIAFNEPGSSLVSRTRLKTLAMDTILANAKYFDGDLSKVPTMALTVGVGTVMDAREVMILITGAHKAFALYKAIEEGVNHMWTVSAFQQHPRTIFVCDEDATLELRVKTVKYFKGLMHVHNKLVDPLFSMKDGN |
| 分子量 | 57.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人GNPDA2蛋白的假设性参考文献及摘要概括，供参考：
---
1. **文献名称**：*Expression and Enzymatic Characterization of Recombinant Human GNPDA2 in E. coli*
**作者**：Zhang Y. et al. (2020)
**摘要**：报道了利用大肠杆菌系统高效表达并纯化重组人GNPDA2蛋白的方法，通过酶动力学分析揭示了其对底物葡萄糖胺-6-磷酸的催化活性，表明其在己糖胺代谢通路中的潜在作用。
2. **文献名称**：*GNPDA2 Deficiency Alters Adipose Tissue Metabolism and Promotes Obesity Resistance*
**作者**：Smith R.L. et al. (2018)
**摘要**：研究发现GNPDA2基因敲除小鼠表现出显著肥胖抵抗表型，重组蛋白实验证实GNPDA2通过调控脂肪细胞内的己糖胺代谢通路，影响脂质储存和能量代谢平衡。
3. **文献名称**：*Crystal Structure of Human GNPDA2 Reveals Substrate Binding Mechanism*
**作者**：Chen X. et al. (2021)
**摘要**：通过X射线晶体学解析了重组人GNPDA2蛋白的三维结构，揭示了其催化活性位点的关键氨基酸残基，为靶向该蛋白的抑制剂设计提供了结构基础。
4. **文献名称**：*GNPDA2 Modulates Apoptosis in Cancer Cells Under Metabolic Stress*
**作者**：Lee J. et al. (2019)
**摘要**：证明重组人GNPDA2蛋白在肿瘤细胞中通过调节葡萄糖代谢中间产物水平，影响内质网应激反应，进而调控细胞凋亡进程，提示其作为癌症治疗新靶点的潜力。
---
注：以上文献信息为假设性示例，具体研究需查阅真实数据库。建议通过PubMed、Web of Science等平台以“GNPDA2”“recombinant protein”等关键词检索最新文献。
Recombinant human GNPDA2 (glucosamine-6-phosphate deaminase 2) is a genetically engineered protein derived from the human GNPDA2 gene, which encodes a metabolic enzyme involved in the hexosamine biosynthesis pathway. This enzyme catalyzes the reversible conversion of glucosamine-6-phosphate (GlcN-6-P) into fructose-6-phosphate and ammonia, playing a regulatory role in cellular energy metabolism and nutrient sensing. GNPDA2 is structurally related to its isoform GNPDA1 but exhibits distinct tissue expression patterns, with higher abundance in the brain, liver, and adipose tissue. Dysregulation of GNPDA2 has been implicated in metabolic disorders, including obesity and diabetes, as well as certain cancers, likely due to its influence on UDP-N-acetylglucosamine levels—a critical substrate for protein glycosylation. Recombinant production typically involves heterologous expression systems (e.g., *E. coli* or mammalian cells) to generate soluble, functional protein for biochemical studies. Purified recombinant GNPDA2 enables detailed investigation of its enzymatic kinetics, substrate specificity, and interactions with potential inhibitors or activators. Recent research also explores its role in cellular stress responses and epigenetic regulation, positioning it as a potential therapeutic target or biomarker for metabolic diseases. Structural studies using recombinant protein have revealed key residues involved in catalysis and substrate recognition, providing insights for drug design.
×
